Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Universityof Kentucky, Lexington, Kentucky 40536-0284, USA.
J Trauma Acute Care Surg. 2012 Aug;73(2):492-7. doi: 10.1097/ta.0b013e31825b85f1.
Antiplatelet drugs (APDs) are among the most commonly prescribed medications.We wondered whether patients with trauma receiving preinjury APD have worse outcomes.
We interrogated our institutional database during a 5-year period to evaluate preoperative risks and trauma outcomes in patients taking APDs before traumatic injury. We used propensity balancing scores to adjust for preoperative risks in assessing outcomes in APD-treated patients.
During a 5-year period, 1,327 (11.7%) of 11,374 adult patients with trauma took APDs before injury. The yearly use of APD in patients with trauma increased nearly threefold during the study period. Cardiac, pulmonary, and renal comorbidities were significantly more common in APD-treated patients. Multivariate regression indicated that preinjury APDs predicted significantly worse composite morbidity and mortality. After propensity adjustment for preinjury risk factors, APD-treated patients demonstrated significantly increased composite morbidity (39.0 vs. 24.6%, p = 0.037) and cardiac complications (23.0 vs. 17.3%, p = 0.017) compared with patients without APDs. The type and intensity of APD conferred an incremental risk, with patients taking dual APDs having a significantly worse multivariate risk of adverse outcomes compared with patients taking a single APD.
APD-treated patients with trauma have significantly more comorbidities compared with those not taking APDs. After adjusting for preoperative risks, APD-treated patients have significantly worse trauma outcomes. Dual APD treatment confers an incremental risk of adverse outcomes compared with single APD preinjury treatment. The number of patients with trauma taking APDs increased during the 5-year study period, so we speculate that trauma management of patients taking APDs will occur more commonly in the future.
抗血小板药物 (APD) 是最常开的药物之一。我们想知道在创伤前接受 APD 治疗的患者是否预后更差。
我们在五年期间对我们的机构数据库进行了查询,以评估术前风险和创伤后接受 APD 治疗的患者的创伤结局。我们使用倾向评分平衡来调整术前风险,以评估 APD 治疗患者的结局。
在五年期间,11374 名成年创伤患者中有 1327 名(11.7%)在受伤前服用了 APD。在研究期间,创伤患者中 APD 的年使用率几乎增加了两倍。APD 治疗患者的心脏、肺部和肾脏合并症明显更常见。多变量回归表明,创伤前 APD 明显预示着复合发病率和死亡率更高。在对术前危险因素进行倾向评分调整后,与未服用 APD 的患者相比,APD 治疗患者的复合发病率(39.0% vs. 24.6%,p=0.037)和心脏并发症(23.0% vs. 17.3%,p=0.017)显著更高。APD 的类型和强度带来了额外的风险,与服用单一 APD 的患者相比,服用双重 APD 的患者发生不良结局的多变量风险显著更高。
与未服用 APD 的患者相比,创伤前接受 APD 治疗的患者合并症更多。在调整了术前风险后,APD 治疗患者的创伤结局明显更差。与单一 APD 治疗相比,双重 APD 治疗的不良结局风险更高。在五年的研究期间,接受 APD 治疗的创伤患者数量有所增加,因此我们推测未来将更常见地对接受 APD 治疗的创伤患者进行管理。